CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.399
EU - Europa 7.062
AS - Asia 5.429
SA - Sud America 716
AF - Africa 150
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 5
Totale 20.778
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.269
RU - Federazione Russa 2.759
SG - Singapore 2.111
CN - Cina 1.791
GB - Regno Unito 1.250
IT - Italia 742
BR - Brasile 562
SE - Svezia 515
VN - Vietnam 487
HK - Hong Kong 464
DE - Germania 446
FR - Francia 367
IE - Irlanda 367
FI - Finlandia 259
KR - Corea 174
UA - Ucraina 83
CA - Canada 73
IN - India 66
NL - Olanda 59
AR - Argentina 56
JP - Giappone 48
TR - Turchia 43
BD - Bangladesh 41
NG - Nigeria 36
ZA - Sudafrica 36
AT - Austria 35
MX - Messico 35
PL - Polonia 32
ES - Italia 29
ID - Indonesia 29
IQ - Iraq 24
EC - Ecuador 22
BE - Belgio 21
SA - Arabia Saudita 20
VE - Venezuela 18
PY - Paraguay 17
TG - Togo 17
AU - Australia 16
CL - Cile 16
PK - Pakistan 16
BJ - Benin 15
JO - Giordania 15
MA - Marocco 15
CH - Svizzera 14
PH - Filippine 14
UZ - Uzbekistan 13
CZ - Repubblica Ceca 12
CO - Colombia 11
LT - Lituania 11
PT - Portogallo 11
IR - Iran 8
MY - Malesia 8
DZ - Algeria 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
KE - Kenya 6
NP - Nepal 6
AL - Albania 5
AZ - Azerbaigian 5
KG - Kirghizistan 5
UY - Uruguay 5
BG - Bulgaria 4
BY - Bielorussia 4
EE - Estonia 4
EG - Egitto 4
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
KZ - Kazakistan 4
LK - Sri Lanka 4
NO - Norvegia 4
PA - Panama 4
QA - Qatar 4
RO - Romania 4
SN - Senegal 4
AM - Armenia 3
CR - Costa Rica 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
BO - Bolivia 2
CI - Costa d'Avorio 2
JM - Giamaica 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BT - Bhutan 1
CG - Congo 1
DM - Dominica 1
Totale 20.758
Salva come PNG Salva come JPEG
Città #
Singapore 1.101
Southend 1.033
Ashburn 980
Moscow 933
Chandler 841
San Jose 707
Dallas 634
Jacksonville 489
Hong Kong 461
Woodbridge 400
Dublin 365
Verona 307
The Dalles 278
Beijing 271
Ann Arbor 268
Ho Chi Minh City 178
Jinan 162
Houston 137
Lawrence 132
Princeton 132
Wilmington 126
Munich 122
Los Angeles 121
New York 115
Shenyang 97
Hanoi 94
Nanjing 89
Helsinki 82
Tianjin 78
Buffalo 70
Hebei 66
São Paulo 60
Redondo Beach 54
Changsha 53
Columbus 52
Zhengzhou 47
Sindelfingen 45
Haikou 44
Milan 44
Frankfurt am Main 42
Santa Clara 42
Turku 42
Orem 39
Taiyuan 39
Tokyo 39
Hangzhou 38
Guangzhou 36
London 36
Redwood City 35
Abuja 34
Nanchang 31
Ningbo 31
Taizhou 31
Johannesburg 26
Seattle 26
Toronto 26
Warsaw 26
Atlanta 25
Council Bluffs 25
Fuzhou 25
Montreal 25
Rome 25
Washington 25
Da Nang 23
Nuremberg 23
Rio de Janeiro 23
Amsterdam 22
Boardman 22
Denver 22
Redmond 22
San Francisco 22
Kent 21
Brussels 20
Chicago 20
Dong Ket 20
Jiaxing 20
Jakarta 19
Brooklyn 18
Vienna 18
Boston 17
Lomé 17
Norwalk 17
Phoenix 17
Barnet 16
Belo Horizonte 15
Brasília 15
Cotonou 15
Haiphong 15
Seoul 15
Stockholm 15
Amman 14
Bologna 14
Chennai 14
Dongguan 14
Lanzhou 13
Zurich 13
Ankara 12
Baghdad 12
Campinas 12
Mexico City 12
Totale 12.676
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 315
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 282
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 255
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 252
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 246
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 232
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 232
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 214
NF-κB as a target for pancreatic cancer therapy. 208
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 201
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 199
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 198
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 198
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 191
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 190
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 189
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 187
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 187
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 187
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 186
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 184
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 183
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 183
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 182
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 181
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 181
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 181
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 179
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 177
The development of PARP as a successful target for cancer therapy 175
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 175
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 173
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 173
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 173
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 173
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 173
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 170
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 170
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 168
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 167
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 165
Pancreatic Cancer: between bench and bedside. 163
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 162
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 161
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 161
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 160
EMT and Treatment Resistance in Pancreatic Cancer 160
ESGAR 2018 Book of Abstracts 154
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 154
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 153
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion 153
Angiogenesis: A target for cancer therapy. 152
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 152
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 152
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 151
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 151
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 149
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 149
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 148
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 148
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma 145
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 145
Toll-Like Receptor 9 Agonists for Cancer Therapy 142
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 141
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 140
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 140
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 136
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial 135
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 134
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 134
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports 132
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 130
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 130
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 130
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 127
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 126
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 125
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 124
Rare secondary tumors of the pancreas 124
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 124
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 123
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 121
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 121
The curious case of Gαs gain-of-function in neoplasia 121
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 121
The Multifaceted Role of TGF-β in Gastrointestinal Tumors 121
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 119
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 119
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 118
Permissive State of EMT: The Role of Immune Cell Compartment 118
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) 117
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer 116
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells 116
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 116
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 116
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 116
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 115
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy 115
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. 114
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis 114
Totale 15.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.385
article - articoli 61.216
book - libri 0
conference - conferenze 8.495
curatela - curatele 0
other - altro 462
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.212
Totale 142.770
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021244 0 0 0 0 0 0 0 0 0 58 107 79
2021/20221.221 87 433 13 167 15 15 9 62 38 22 68 292
2022/20232.311 180 234 221 357 209 553 28 138 293 23 49 26
2023/20241.331 43 101 94 123 164 183 116 166 15 71 198 57
2024/20253.233 167 191 110 510 138 99 177 160 491 200 311 679
2025/20268.764 686 430 685 1.424 2.274 625 894 487 733 526 0 0
Totale 20.973